Clinical Trial Update: Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus, tacrolimus, thymoglobulin, and rituximab as graft-versus-host-disease prophylaxis in haploidentical and partially HLA-matche…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Lymphoma
• Lymphoproliferative Disorder
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Disorders

Drugs mentioned

• Rituximab (rituximab)
• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Status: TERMINATED | Results posted: 2013-12-13